The U.S. has approved long-acting injectable PrEP options such as cabotegravir (Apretude) and lenacapavir (Yzugo), yet major challenges remain around equitable access, demand generation, and health-system readiness. This project explores what the United States can learn from low- and middle-income countries (LMICs) that successfully expanded injectable contraceptives, an intervention with striking parallels to injectable PrEP.
Information on credits offered to SYNC participants for attending institutes, sessions, and plenaries — live or in-person — is available here.
Commercial Support Acknowledgement
This conference is supported, in part, by independent educational grants from ineligible companies. A full list of supporters is available here. All accredited content has been developed and delivered in accordance with the ACCME Standards for Integrity and Independence and the criteria of Joint Accreditation for Interprofessional Continuing Education™, and is free of commercial bias.
POZ
ChemBio
Important Notice: We have received reports of companies falsely claiming to sell SYNChronicity Conference attendee lists and related services. These solicitations are scams and are not affiliated with SYNChronicity, HealthHIV, HealthHCV, or the National Coalition for LGBTQ Health. Do not engage with these organizations. For questions about conference communications or vendors, contact us directly.
The U.S. has approved long-acting injectable PrEP options such as cabotegravir (Apretude) and lenacapavir (Yzugo), yet major challenges remain around equitable access, demand generation, and health-system readiness. This project explores what the United States can learn from low- and middle-income countries (LMICs) that successfully expanded injectable contraceptives, an intervention with striking parallels to injectable PrEP.
